On 22 June, 2017 the global kidney cancer community of patients, caregivers, families, healthcare professionals and patient organisations came together to celebrate our inaugural World Kidney Cancer Q & A Day.
Our aim was to raise much needed awareness of kidney cancer around the world by asking those who visited our website to take the brief 7 question Quiz. Over 11,000 people from Ghana to Australia completed our seven-question online Quiz and helped raise funds at the same time. A report
Our seventh IKCC Conference for kidney cancer patient organisations recently held in Warsaw, Poland was a huge success. The first ever Global Kidney Cancer Awareness Day – Thursday 22nd June 2017 – was officially launched following the keynote address on the ‘Global Burden of Kidney Cancer’ delivered by Prof. Dr. Hendrik van Poppel of Belgium.
During the AGM, Dr. Eric Jonasch, an internationally recognized expert specialising in kidney cancer from Texas, USA and Dr. Elizabeth Perdeaux
Immuno-oncology (IO) therapy is a new (and old) way to treat cancer by activating your immune system in the hope that it will attack your tumour. Our sister site ‘10-for-IO’ is a central resource for patient organisations to access information about immuno-oncology specifically as it applies to renal cell carcinoma. Click here for more information.
We are pleased to present the Book of Courage and Hope. This collection of the stories of patient experiences and the support provided by our affiliates in many of the countries represented among our Affiliates helps to demonstrate the important work of our Affiliates, and of the International Kidney Cancer Coalition in supporting and encouraging those Affiliates. Read about the important work of kidney cancer care around the world.
Our International Kidney Cancer Patient Charter was created to ensure that the more than one million people living with kidney cancer worldwide have access to the best available treatment, care, information and support. The Charter is based on a survey extended to 34 patient group leaders with a special interest in kidney cancer, located in 20 countries spread over 6 continents.
Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse. Read more
